CYTOMX THERAPEUTICS INC

NASDAQ: CTMX (CytomX Therapeutics, Inc.)

Last update: 23 minutes ago

2.02

-0.02 (-1.23%)

Previous Close 2.04
Volume 693,367
Price / Sales 28.42
Price / Book 1.55
52 Weeks Range
1.90 (-5%) — 8.21 (307%)
Profit Margin 28.19%
Operating Margin (TTM) 44.43%
Diluted EPS (TTM) 0.480
Quarterly Revenue Growth (YOY) 22.80%
Quarterly Earnings Growth (YOY) 70.60%
Total Debt/Equity (MRQ) 32.53%
Current Ratio (MRQ) 1.73
Operating Cash Flow (TTM) -81.23 M
Levered Free Cash Flow (TTM) -53.07 M
Return on Assets (TTM) 15.87%

AIStockmoo Score

-0.3
Value 30% 3.4
From our AI Insight report's view of expected return against risk. info NA
Priced low for its earnings growth. info
Implied Growth info NA
Valuation History info NA
Low debt. Strong profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 30% -4.0
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Smart Money 20% -0.7
Insider Activity info NA
Institutions net -0.08% of shares in their latest 13F filings: 114 holders increased, 75 decreased (quarter to 30 Sep 2026). info
Short interest +35.0% from 31 Aug to 30 Oct 2026, 12 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is between support and resistance. Levels trending up. info
Final Score -0.30

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock CytomX Therapeutics, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CTMX - - - 1.55
OPT 583 M - - 4.31
OCUP 51 M - - 0.870
ZYME - - - 7.29
PBYI - - - 2.73
ORMP - 6.74% - 0.530

Select this tab to load the latest available analysis.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 0.83%
% Held by Institutions 47.10%

Ownership

Name Date Shares Held
Elmind Capital, Lp 30 Jun 2026 4,550,000

No data within this time range.

Institutions

Institutional ownership: 103.35%

Positions Holders Shares
Increased 114 29,761,343
Decreased 75 28,757,015
New 46 5,112,628
Sold out 32 6,286,727

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 45,246,966 12.0
15 Oct 2026 42,790,446 13.8
30 Sep 2026 40,813,393 8.7
15 Sep 2026 38,639,220 9.3
31 Aug 2026 33,512,293 11.8
14 Aug 2026 34,619,999 15.9

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 1 Negative 4 Neutral
Date Type Details
06 Nov 2026 Yahoo Finance CytomX (CTMX) Q3 2026 Earnings Call Transcript
Lower diarrhea rates emerge, but toxicity control remains the key test.
05 Nov 2026 Yahoo Finance CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data…
05 Nov 2026 Yahoo Finance CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
05 Nov 2026 Yahoo Finance CytomX Therapeutics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc.
05 Nov 2026 Yahoo Finance CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase…
02 Nov 2026 Yahoo Finance CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual…
29 Oct 2026 Yahoo Finance CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S.…
01 Sep 2026 Yahoo Finance CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual…
27 Aug 2026 Yahoo Finance CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.…

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria